Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma

Annals of Surgical Oncology

Volumn 12, Issue 12, 2005, Pages 995-1004

  Pipas, J Marc ^a   Barth Jr , Richard J ^a   Zaki, Bassem ^a   Tsapakos, Michael J ^a   Suriawinata, Arief A ^a   Bettmann, Michael A ^a,b   Cates, Justin M ^a,c   Ripple, Gregory H ^a   Sutton, John E ^a   Gordon, Stuart R ^a   McDonnell, Carol E ^a   Perez, Raymond P ^a   Redfield, Nancy ^a   Meyer, Louise P ^a   Marshall, John F ^a   Cole, Bernard F ^a   Colacchio, Thomas A ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Docetaxel; Gemcitabine; Neoadjuvant; Pancreatic adenocarcinoma; Radiotherapy

Indexed keywords

ALBUMIN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GLUCOSE; PROTON PUMP INHIBITOR; SODIUM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT RESPIRATORY DISTRESS SYNDROME; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BEAM THERAPY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELLULITIS; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG FATALITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALBUMINEMIA; HYPERGLYCEMIA; HYPONATREMIA; LEUKOPENIA; LIVER FUNCTION TEST; MYALGIA; MYOSITIS; NAUSEA; NEUTROPENIA; PAIN; PANCREAS ADENOCARCINOMA; PNEUMOCYSTIS PNEUMONIA; RADIOGRAPHY; RASH; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TAXOIDS;

EID: 27844451971     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2005.04.503     Document Type: Article

References (39)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer. J Clin 2004;54:8-29.
2. Evans D, Abbruzzese JL, Rich TA. (2001) Cancer of the pancreas. In: Devitas V, Helmann S, Rosenbergh S (eds). Cancer: Principles and Practice of Oncology. 6th ed Lippincott Williams & Wilkins, Philadelphia, pp 1126-61.
3. Wolff RA. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas: great logic, grim reality (comment). Ann Surg Oncol 2001;8:747-8.
4. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996;171:118-24.
5. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-7.
6. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 1979;189:205-8.
7. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-37.
8. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22:42-6.
9. Fossella F. Dose scheduling and dosage of gemcitabine. In: Bunn P, ed. 7th World Conference on Lung Cancer, Colorado Springs, CO: International Association for the Study of Lung Cancer, 1994.
10. Shewach DS, Lawrence TS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 1995;22:68-71.
11. Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000;47:785-91.
12. Pipas JM, Mitchell SE, Barth RJ Jr, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001;50:1317-22.
13. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-12.
14. American Society of Health-System Pharmacists. American Hospital Formulary Service: Drug Information. Bethesda, MD: American Hospital Formulary Service, 2003:966-71.
15. Abbruzzese J, Evans D, Gravel D, Markowitz A, Patt Y, Pazdur R. Docetaxel, a potentially active agent for patients with pancreatic adenocarcinomas. In: 1995 ASCO Annual Meeting, 1995.
16. Rougier P, Adenis A, Ducreaux M. A phase II study of docetaxel (Taxotere) in pancreatic adenocarcinoma: final results after extra mural review (abstr). In: Second International Conference on Biology, Prevention, and Treatment of Gastrointestinal Malignancies, Koln, Germany, 1995.
17. De Forni M, Rougier P, Adenis A, et al. A phase II study of docetaxel (RP 56976, Taxotere) in locally advanced and/or metastatic pancreatic cancer (abstr). Ann Oncol 1994;5:S202.
18. Ducreax M, Adenis A, Blanc C, et al. Phase II study of docetaxel in pancreatic cancer. Ann Oncol 1994;5:S82.
19. Olszanski A, Rigas JR. Docetaxel and gemcitabine: a non-platinum combination for non-small cell lung cancer. Clin Lung Cancer 2000;1:S15-9.
20. Rigas J, Rothenberg M, Davis T, et al. Phase I clinical and pharmacokinetic study of docetaxel with two gemcitabine infusion schedules (abstr). Proc Am Soc Clin Oncol 1999;18:226.
21. Petrovic Z. Docetaxel and gemcitabine in patients with advanced pancreatic cancer (abstr). Proc Am Soc Clin Oncol 2001;20:129.
22. Cao MG, Salgado E, Rodríguez J, Ordoñez JM, Calvo E, Martin S. Docetaxel with gemcitabine in metastatic pancreatic cancer (abstr). Proc Am Soc Clin Oncol 2001;20:131.
23. Ryan DP, Kulke MH, Fuchs CS, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002;94:97-103.
24. Fahlke J, Ridwelski K, Schmidt C, et al. Docetaxel/gemcitabine as first-line treatment of locally advanced or metastatic pancreatic cancer: phase II results (abstr). Proc Am Soc Clin Oncol 2004;23:337.
25. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168:1439-43.
26. O'Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR Am J Roentgenol 1999;173:1513-8.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
28. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-9.
29. Royal R. The multimodality treatment of patients with pancreatic cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Principles and Practices of Oncology Updates. 2004:1-16.
30. Willett CG, Safran H, Abrams RA, Regine WF, Rich TA. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2003;56:31-7.
31. Green N, Beron E, Melbye RW, George FW III. Carcinoma of pancreas - palliative radiotherapy. Am J Roentgenol Radium Ther Nucl Med 1973;117:620-2.
32. Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000;135:81-7.
33. Ashamalla H, Zaki B, Mokhtar B, et al. Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:679-87.
34. Poggi MM, Kroog GS, Russo A, et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;54:670-6.
35. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-8.
36. Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000;18:3384-9.
37. Martenson JA, Vigliotti AP, Pitot HC, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1305-10.
38. Gnant MF, Irene Kuehrer BT, Goetzinger P, et al. Neoadjuvant chemotherapy with gemcitabine and docetaxel for locally advanced pancreatic cancer (abstr). Proc Am Soc Clin Oncol 2002;21:149.
39. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.